SCHEMBL1858360

SCHEMBL1858360

C[C@H](O)c1ncccc1F

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.41
CYP2D6 P10635 1/20 0.38
CHRM1 P11229 1/20 0.38
HRH1 P35367 1/20 0.38
KCNH2 Q12809 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
KDM4E B2RXH2 3/20 0.36
MPI P34949 1/20 0.36
PDK2 Q15119 1/20 0.35
NAPRT Q6XQN6 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CTH P32929 1/20 0.33
NPC1 O15118 2/20 0.33
PKM P14618 1/20 0.33
AGTR1 P30556 1/20 0.33
RAB9A P51151 1/20 0.33
MAPK1 P28482 1/20 0.32
CNR1 P21554 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25211250 1.00 TRPM8 (0.41) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL506640 1.00 TRPM8 (0.41) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL29858175 1.00 TRPM8 (0.41) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL9963324 0.85 CYP2D6 (0.40) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL12468617 0.83 CYP2D6 (0.38) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL20738494 0.79 CYP2D6 (0.38) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL21547452 0.79 CYP2D6 (0.41) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL20738495 0.79 CYP2D6 (0.38) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL30824594 0.79 CYP2D6 (0.38) TRPM8CYP2D6CHRM1HRH1KCNH2
SCHEMBL6961060 0.79 CYP2D6 (0.38) TRPM8CYP2D6CHRM1HRH1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270211-A1 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. 2025-08-28 US disclosed
US-12351581-B2 Compounds for FGFR inhibition COGENT BIOSCIENCES, INC. (US) 2025-07-08 US disclosed
WO-2025034912-A9 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. (US) 2025-04-24 WO disclosed
US-20250066352-A1 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. 2025-02-27 US disclosed
WO-2025034912-A2 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. (US) 2025-02-13 WO disclosed
US-8158785-B2 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy ASTRAZENECA AB (SE) 2012-04-17 US disclosed
US-8158785-B2 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy ASTRAZENECA AB (SE) 2012-04-17 US disclosed
US-8158785-B2 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy ASTRAZENECA AB (SE) 2012-04-17 US disclosed
CN-101522693-B Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy ASTRAZENECA AB 2012-01-04 CN disclosed
EP-2069364-B1 NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2011-12-14 EP disclosed
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2010-02-11 US disclosed
CN-101522693-A Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy ASTRAZENECA AB (SE) 2009-09-02 CN disclosed
CN-101516893-A Novel 5, 7-disubstituted [1,3] thiazolo [4, 5-D ] pyrimidin-2 (3H) -one derivatives and their use in therapy ASTRAZENECA AB (SE) 2009-08-26 CN disclosed
EP-2069365-A1 NOVEL 5,7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5D]PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY AstraZeneca AB (SE) 2009-06-17 EP disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 US disclosed
WO-2008039139-A1 NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2008-04-03 WO disclosed
WO-2008039139-A1 NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2008-04-03 WO disclosed
WO-2008039138-A1 NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066352-A1 COMPOUNDS FOR FGFR INHIBITION FGFR1, FGFR4, FGFR3 TRPM8 2768/4885CYP2D6 3242/4885CHRM1 3712/4885
US-20080318981-A1 Novel Compounds 480 CX3CR1, CCR2, CXCR3 TRPM8 146/4885CYP2D6 1223/4885CHRM1 10/4885
US-20250270211-A1 COMPOUNDS FOR FGFR INHIBITION FGFR1, FGFR4, FGFR3 TRPM8 2768/4885CYP2D6 3242/4885CHRM1 3712/4885
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY CX3CR1, CCR2, CXCR3 TRPM8 289/4885CYP2D6 1092/4885CHRM1 11/4885
US-12351581-B2 Compounds for FGFR inhibition FGFR1, FGFR4, FGFR3 TRPM8 2768/4885CYP2D6 3242/4885CHRM1 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.